Literature DB >> 1622897

The effect of p56lck, a lymphocyte specific protein tyrosine kinase, on the syncytium formation induced by human immunodeficiency virus envelope glycoprotein.

H Yoshida1, Y Koga, Y Moroi, G Kimura, K Nomoto.   

Abstract

A human CD4+ T cell line, Jurkat, was transfected with a constructed plasmid, which has the envelope gene of the human immunodeficiency virus (HIV) under the transcriptional control of the human metallothionein IIA promoter, and these transfected cells were then cloned. JME2, one of the cloned cell lines, expressing the envelope glycoprotein after induction with metal ions, showed the ability to form syncytia involving other CD4+ cells not expressing the HIV envelope protein. When several CD4+ cell lines were examined for their susceptibility to syncytium formation by JME2 cells, the p56lck-expressing cell lines were found to be more susceptible to syncytium formation than the p56lck-non-expressing cell lines. To substantiate the role of p56lck in the syncytium formation, a CD4+, p56lck-non-expressing monocytoid cell line, U937 clone 2, was transfected with an lck-expressing construct. Using such transfectant cell clones, it was demonstrated that p56lck-positive cells are markedly more susceptible to the syncytium formation than p56lck-negative cells, implying a regulatory role for p56lck in syncytium formation mediated by the HIV envelope and CD4 molecule. Moreover, it was suggested, in the experiments using CD45 cross-linking or a protein tyrosine kinase inhibitor, genistein, that p56lck affects syncytium formation through its protein tyrosine kinase activity. A putative mechanism by which p56lck affects the syncytium formation is also discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622897     DOI: 10.1093/intimm/4.2.233

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway.

Authors:  W Popik; P M Pitha
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

2.  Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells.

Authors:  Mathias Viard; Isabella Parolini; Massimo Sargiacomo; Katia Fecchi; Carlo Ramoni; Sherimay Ablan; Francis W Ruscetti; Ji Ming Wang; Robert Blumenthal
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages.

Authors:  Tzanko S Stantchev; Ingrid Markovic; William G Telford; Kathleen A Clouse; Christopher C Broder
Journal:  Virus Res       Date:  2006-10-09       Impact factor: 3.303

Review 4.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

5.  Glycosylphosphatidylinositol-anchored CD4 supports human immunodeficiency virus type 1 replication, but not cytopathic effect, in T-cell transfectants.

Authors:  W L Marshall; E S Mittler; P Avery; J P Lawrence; R W Finberg
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death.

Authors:  V Kolesnitchenko; L M Wahl; H Tian; I Sunila; Y Tani; D P Hartmann; J Cossman; M Raffeld; J Orenstein; L E Samelson; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  The Src kinase Lck facilitates assembly of HIV-1 at the plasma membrane.

Authors:  Amy B Strasner; Malini Natarajan; Tom Doman; Douglas Key; Avery August; Andrew J Henderson
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

8.  Phosphatidylinositol (PI) 3-kinase and PI 4-kinase binding to the CD4-p56lck complex: the p56lck SH3 domain binds to PI 3-kinase but not PI 4-kinase.

Authors:  K V Prasad; R Kapeller; O Janssen; H Repke; J S Duke-Cohan; L C Cantley; C E Rudd
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.